These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1838142)

  • 1. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
    Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC
    Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
    Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
    Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W
    Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
    Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
    Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
    Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
    J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
    Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
    J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.